Pre-earnings brief
Reports
Fri, Oct 30, 2026
Est. EPS
—
Est. revenue
—
Implied move
±3.7%
EPS beat rate
100%
Sanofi (SNY) is a global healthcare company focused on pharmaceuticals and vaccines. With a market cap of $96 billion, it plays a crucial role in addressing various health needs, particularly in areas like diabetes, oncology, and vaccines, which are increasingly relevant in today's health landscape.
Last quarter
In Q1 2012, Sanofi reported an EPS of $2.45, significantly beating estimates by 116.64%. The stock reacted positively, gaining 2.28% the following day.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+120.71%
Avg 1-day reaction
+1.51%
Overall expectations for Sanofi's upcoming earnings are mixed, with investors hoping for continued strong performance based on past results.
Bull case
If Sanofi continues its trend of beating EPS estimates, it could lead to a positive market reaction, reinforcing investor confidence.
Bear case
On the other hand, any signs of slowing revenue growth or increased competition could lead to a negative reaction from the market.
Key metrics to watch
Earnings Per Share (EPS)
Expectations are not available.EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue Growth
Expectations are not available.Revenue growth reflects the company's ability to expand its market presence and product sales, crucial for long-term success.
The print will turn on these.
Q1
What will be the EPS for Q2 2012?
Given the company's strong history of beating EPS estimates, this figure will be critical in shaping investor sentiment.
Q2
How is revenue growth trending in key segments?
Understanding revenue performance in critical areas like diabetes and vaccines will help gauge the company's future prospects.
—
Est. EPS
$6.73
Est. Rev
$4.6B
Impl. Move
±2.6%
Why consensus could be wrong
The Street may underestimate Sanofi's ability to sustain high EPS growth due to its strong pipeline and market position.
Supporting evidence
Sanofi has consistently beaten EPS estimates, indicating strong operational performance.
The options market is pricing a modest move, suggesting that traders may not fully appreciate the potential upside.
Key risk
If the EPS comes in significantly above $2.50, it could challenge current bearish sentiment.
Pre-commit to what would confirm each case.
The market is watching closely for signs of continued growth and profitability, especially after the strong performance in the previous quarter.
Bull confirmed if
An EPS of $2.50 or higher would confirm the bull case, indicating strong profitability.
Bear confirmed if
An EPS below $2.00 would confirm the bear case, suggesting potential challenges ahead.
What the market is pricing for the move.
Implied Move
±3.68%
Historical Avg
±3.1%
The options market is pricing in a potential move of about 3.68% following the earnings report, indicating some uncertainty among traders.
Options are pricing ±3.7% while SNY has averaged ±3.1% over the last 8 prints — setup is pricing rich.
ATM IV
0.3%
30d HV
17.3%
Smart-money positioning from the most recent 13F filings.
Institutional
8.02%
of float
Insider
0.00%
of float
Holders
847
institutions
Top Holders· as of Jun 2026
Dodge & Cox Inc.
28,088,274 sh · $1.1B
10.54%
-4.8%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Sanofi beats expectations, history suggests the stock could rise by around 1.51%, confirming positive market sentiment.
In line / cautious
If results are in line but management is cautious, the stock may react neutrally, reflecting uncertainty.
Miss
A miss could lead to a decline, with historical averages suggesting a potential drop of around 3.12%.
The lines on the call that would change the story.
Morgan Stanley
10,702,527 sh · $430.2M
4.02%
-14.5%
Fisher Asset Management, LLC
10,627,088 sh · $427.2M
3.99%
-7.1%
Bank of America Corporation
8,008,572 sh · $321.9M
3.00%
-15.6%
Invesco Ltd.
6,798,961 sh · $273.3M
2.55%
2.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.